A carregar...

Renal Impairment, C. difficile Recurrence, and the Differential Effect of Bezlotoxumab: A Post Hoc Analysis of Pooled Data From 2 Randomized Clinical Trials

BACKGROUND: Renal impairment is not a consistently cited risk factor for recurrent Clostridioides difficile infection (rCDI). We examined the association between renal impairment and rCDI and the effect of bezlotoxumab, an anti–toxin B monoclonal antibody, in reducing rCDI in participants with renal...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Open Forum Infect Dis
Main Authors: Golan, Yoav, DuPont, Herbert L, Aldomiro, Fernando, Jensen, Erin H, Hanson, Mary E, Dorr, Mary Beth
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2020
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7357450/
https://ncbi.nlm.nih.gov/pubmed/32685606
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ofid/ofaa248
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!